After adjustment for the effects of age at diagnosis, PSA levels at diagnosis, clinical T stage, pathologic T stage, pathologic N stage, pathologic Gleason grade group, perineural invasion, seminal vesicle invasion, lymphovascular invasion, biochemical recurrence and D’Amico classification, a significant difference (p = 0.019) and adjusted odds ratios (AORs) = 0.628 with CIs = 0.426–0.926 was observed in prostate cancer patients with or without grade group upgrade with RAGE rs2070600 ‘GA’ genotype compared with the wild‐type (WT) ‘GG’ carriers (Table 2). Here, AGER is linked to prostate cancer.